Evaluates direct oral anticoagulant plasma testing across hemostasis laboratories, highlighting clinical scenarios that justify drug level measurement despite standard fixed-dose regimens.
Direct oral anticoagulants (DOACs) reflect anticoagulation agents given to treat or prevent thrombosis, having largely replaced vitamin K antagonists (VKAs) such as warfarin. DOACs are given in fixed daily doses and generally do not need monitoring. However, there may be a variety of reasons that justify measurement of plasma DOAC levels in individual patients.
No takes yet. Share an insight, caveat, or question.
Favaloro et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: